Astellas US Technologies
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$17.5M
Doctors Paid
2
Transactions
1,877
2024 Total
$6.9M
Payment Breakdown by Category
Research$17.5M (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $17.5M | 1,877 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Enfortumab Vedotin and Pembrolizumab Prior to Cystectomy for Locally Advanced Urothelial Cancer | $3.4M | 0 | 28 |
| A Phase II Open-Label Study of Enfortumab Vedotin in Patients with Previously Treated Locally Advanced, Recurrent, or Metastatic Pancreatic Adenocarcinoma (EPIC) | $2.8M | 0 | 14 |
| A Phase II Open-Label Study of Enfortumab Vedotin with or without Pembrolizumab in Patients with Previously Treated Locally Advanced, Recurrent, or Metastatic Pancreatic Adenocarcinoma | $1.7M | 0 | 12 |
| ENCORE: A Phase 2 Umbrella Protocol of Enfortumab Vedotin as Monotherapy and Combined with Other Agents in Patients with Metastatic Castration-Resistant Prostate Cancer | $1.5M | 0 | 9 |
| ENCORE A Phase 2 Umbrella Protocol of Enfortumab Vedotin as Monotherapy and Combined with Other Agents in Patients with Metastatic Castration Resistant Prostate Cancer | $1.2M | 0 | 6 |
| ENCORE: A Phase 2 Umbrella Protocol of Enfortumab Vedotin as Monotherapy and Combined with Other Agents in Patients with Metastatic Castration-Resistant Prostate Cancer | $1.2M | 0 | 5 |
| MC200505 Phase II Study of Enfortumab Vedotin Treatment for Metastatic Squamous Cell Carcinoma of the Penis | $953,418 | 0 | 9 |
| A single center open-label trial of isavuconazole prophylaxis against invasive fungal infection in patients undergoing allogeneic hematopoietic stem cell transplant (HCT) | $732,519 | 0 | 2 |
| A phase II study of isavuconazole prophylaxis in adult patients with AML and neutropenia | $554,548 | 0 | 10 |
| Once-a-day Tacrolimus Conversion Study: The OneTAC Trial | $502,997 | 0 | 2 |
| Neoadjuvant Enfortumab Vedotin in High-Grade Urothelial Carcinoma of the Upper Urinary Tract (including Ureter and Renal Pelvis) | $466,330 | 0 | 3 |
| Neoadjuvant Combination Pembrolizumab / Enfortumab Vedotin Prior to Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Carcinoma | $410,114 | 0 | 4 |
| ENCORE A Phase 2 Umbrella Protocol of Enfortumab Vedotin as Monotherapy and Combined with Other Agents in Patients with Metastatic Castration Resistant Prostate Cancer | $306,240 | 0 | 1 |
| Phase II Single-Arm Study of Enfortumab Vedotin (EV) plus Pembrolizumab in the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology | $279,250 | 0 | 3 |
| A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects | $274,173 | 0 | 844 |
| Study Comparing Brand and Generic Immunosuppresion on Transplant Outcomes, Adherence, & Immune Response | $169,865 | 0 | 3 |
| A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS | $167,787 | 2 | 532 |
| A Phase 1 Crossover Study to Assess the Bioequivalence of Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution via Nasogastric Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Subjects | $135,284 | 0 | 4 |
| Stereotactic Treatment with neoAdjuvant Radiotherapy and Enfortumab Vedotin: a Phase I/II Study with Safety Lead-In for localized, cisplatin ineligible, muscle invasive bladder cancer (STAR-EV) | $101,124 | 0 | 1 |
| ENCORE: A Phase 2 Umbrella Protocol of Enfortumab Vedotin as Monotherapy and Combined with Other Agents in Patients with Metastatic Castration-Resistant Prostate Cancer. | $85,140 | 0 | 1 |
| A Prospective, Pilot Trial to Evaluate Safety and Tolerability of Tacrolimus Extended-Release Astagraf XL in HLA Sensitized Kidney Transplant Recipients | $71,986 | 0 | 17 |
| Mirabegron and Urinary Incontinence: The Clinical Response and the Female Urinary Microbiome | $71,968 | 0 | 1 |
| A Prospective, Pilot Trial to Evaluate Safety and Tolerability of Tacrolimus Extended-Release (Astagraf XL) in HLA Sensitized Kidney Transplant Recipients | $64,501 | 0 | 1 |
| A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis IA or Invasive Mucormycosis IM in Pediatric Subjects | $56,139 | 0 | 178 |
| Isavuconazole for the Prevention of SARS-CoV-2-associated Invasive Aspergillosis in Critically-Ill Patients | $42,880 | 0 | 3 |
| Mirabegron and Urinary Incontinence The Clinical Response and the Female Urinary Microbiome | $35,609 | 0 | 1 |
| Assessment of Myocardial Flow Reserve (and Effects of Exercise Traiing in Patients with Angina and Negative Coronary Angiograms | $28,207 | 0 | 1 |
| Mirabegron for Erectile Dysfunction | $20,801 | 0 | 59 |
| Clinical Trial of the Safety and Efficacy of Regadenoson for Moderate to Severe COVID-19 in Adult Patients | $19,770 | 0 | 1 |
| A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IA OR INVASIVE MUCORMYCOSIS IM IN PEDIATRIC SUBJECTS | $18,923 | 0 | 60 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Pediatric Infectious Diseases | $5,677 | 1 | $5,677 |
| Pediatrics | $1,892 | 1 | $1,892 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2020 |
|---|---|---|---|---|
| Dr. William Muller, Md, Phd, MD, PHD | Pediatric Infectious Diseases | Chicago, IL | $5,677 | $0 |
| Victoria Statler, M.d, M.D | Pediatrics | Louisville, KY | $1,892 | $0 |
Ad
Top Products
- Padcev $14.5M
- Cresemba $1.1M
Associated Products (3)
- Padcev $29.0M
- Tacrolimus extended release capsules $727,148
- Tacrolimus capsules $175,269
Payment Categories
- Research $17.5M
About Astellas US Technologies
Astellas US Technologies has made $17.5M in payments to 2 healthcare providers, recorded across 1,877 transactions in the CMS Open Payments database. In 2024, the company paid $6.9M. The top product by payment volume is Padcev ($14.5M).
Payments were distributed across 2 medical specialties. The top specialty by payment amount is Pediatric Infectious Diseases ($5,677 to 1 doctors).
Payment categories include: Research ($17.5M).
Astellas US Technologies is associated with 3 products in the CMS Open Payments database.